Key Laboratory of Surveillance and Early-Warning On Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Department of Epidemiology and Biostatistics, Peking University School of Public Health, Beijing, 100191, China.
BMC Med. 2023 Mar 16;21(1):100. doi: 10.1186/s12916-023-02821-x.
A global plan has been set to end human deaths from dog-mediated rabies by 2030 ("Zero-by-30"), but whether it could be achieved in some countries, such as China, remains unclear. Although elimination strategies through post-exposure prophylaxis (PEP) use, dog vaccination, and patient risk assessments with integrated bite case management (IBCM) were proposed to be cost-effective, evidence is still lacking in China. We aim to evaluate the future burdens of dog-mediated human rabies deaths in the next decade and provide quantitative evidence on the cost-effectiveness of different rabies-control strategies in China.
Based on data from China's national human rabies surveillance system, we used decision-analytic modelling to estimate dog-mediated human rabies death trends in China till 2035. We simulated and compared the expected consequences and costs of different combination strategies of the status quo, improved access to PEP, mass dog vaccination, and use of IBCM.
The predicted human rabies deaths in 2030 in China will be 308 (95%UI: 214-411) and remain stable in the next decade under the status quo. The strategy of improved PEP access alone could only decrease deaths to 212 (95%UI: 147-284) in 2028, remaining unchanged till 2035. In contrast, scaling up dog vaccination to coverage of 70% could eliminate rabies deaths by 2033 and prevent approximately 3,265 (95%UI: 2,477-3,687) extra deaths compared to the status quo during 2024-2035. Moreover, with the addition of IBCM, the "One Health" approach through mass dog vaccination could avoid unnecessary PEP use and substantially reduce total cost from 12.53 (95%UI: 11.71-13.34) to 8.73 (95%UI: 8.09-9.85) billion US dollars. Even if increasing the total costs of IBCM from 100 thousand to 652.10 million US dollars during 2024-2035, the combined strategy of mass dog vaccination and use of IBCM will still dominate, suggesting the robustness of our results.
The combined strategy of mass dog vaccination and IBCM requires collaboration between health and livestock/veterinary sectors, and it could eliminate Chinese rabies deaths as early as 2033, with more deaths averted and less cost, indicating that adding IBCM could reduce unnecessary use of PEP and make the "One Health" rabies-control strategy most cost-effective.
全球计划设定了到 2030 年(“零死亡-30”)终结由犬介导的狂犬病导致人类死亡的目标,但在一些国家(如中国)是否能够实现仍不清楚。尽管通过接触后预防(PEP)使用、犬只疫苗接种和综合咬伤病例管理(IBCM)进行的患者风险评估的消除策略被认为是具有成本效益的,但中国仍缺乏相关证据。我们旨在评估未来十年内由犬介导的人类狂犬病死亡人数,并提供中国不同狂犬病控制策略的成本效益定量证据。
基于中国国家狂犬病监测系统的数据,我们使用决策分析模型来估计 2035 年中国犬介导的人类狂犬病死亡趋势。我们模拟和比较了现状、提高 PEP 可及性、大规模犬只疫苗接种和使用 IBCM 等不同组合策略的预期结果和成本。
预计 2030 年中国的人类狂犬病死亡人数将为 308 人(95%UI:214-411),在现状下未来十年内将保持稳定。仅提高 PEP 可及性的策略只能将 2028 年的死亡人数减少到 212 人(95%UI:147-284),到 2035 年仍保持不变。相比之下,将犬只疫苗接种覆盖率提高到 70%可以在 2033 年前消除狂犬病死亡,并在 2024-2035 年期间与现状相比,预防约 3265 人(95%UI:2477-3687 人)的额外死亡。此外,通过大规模犬只疫苗接种和 IBCM 的“同一健康”方法,可以避免不必要的 PEP 使用,并将总成本从 125.30 亿美元(95%UI:117.10-133.40 亿美元)大幅减少到 87.30 亿美元(95%UI:80.90-98.50 亿美元)。即使在 2024-2035 年期间将 IBCM 的总成本从 100 万美元增加到 6.521 亿美元,大规模犬只疫苗接种和 IBCM 的联合策略仍将占据主导地位,表明我们的结果具有稳健性。
大规模犬只疫苗接种和 IBCM 的联合策略需要卫生和牲畜/兽医部门之间的合作,它可以最早在 2033 年消除中国的狂犬病死亡,从而避免更多的死亡和减少成本,这表明添加 IBCM 可以减少不必要的 PEP 使用,并使“同一健康”狂犬病控制策略具有最高的成本效益。